Role of the ubiquitin-proteasome protein degradation pathway in carcinogenesis, tumor progression and susceptibility to tumor treatment

Experimental Oncology

Volumn 24, Issue 4, 2002, Pages 243-248

  Sjakste, N ^a   Sjakste, T ^a   Vikmanis, U ^a  

^a UNIVERSITY OF LATVIA   (Latvia)

Author keywords

Cancer; Proteasomes

Indexed keywords

CD23 ANTIGEN; HYPOXIA INDUCIBLE FACTOR 1ALPHA; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PROTEASOME; PROTEASOME INHIBITOR; PROTEIN BCL 2; PROTEIN P21; UBIQUITIN;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; CANCER INHIBITION; CANCER PREVENTION; CANCER SUSCEPTIBILITY; CARCINOGENESIS; CELL PROLIFERATION; CHEMICAL CARCINOGENESIS; HUMAN; NONHUMAN; ONCOGENE; PROTEIN DEGRADATION; REVIEW; SIGNAL TRANSDUCTION; VIRUS CARCINOGENESIS;

EID: 0036971557     PISSN: 02043564     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (70)

1. Almond JB, Cohen JM. The proteasome: a novel target for cancer chemotherapy. Leukemia 2002; 16: 433-41.
2. Bahram F, von der Lehr N, Cetinkaya C, Larsson LG. c-Myc hot spot mutations in lymphomas result in inefficient ubiquitination and decreased proteasome-mediated turnover. Blood 2000; 95: 2104-10.
3. Benvenuto G, Li S, Brown SJ, Braverman R, Vass WC, Cheadle JP, Halley DJ, Sampson JR, Wieneeke R, DeClue JE. The tuberous sclerosis-1 (TSC1) gene product hamartin suppresses cell growth and augments the expression of the TSC2 product tuberin by inhibiting its ubiquitination. Oncogene 2000; 19: 6306-16.
4. Berezutskaya E, Bagehi S. The human papillomavirus E7 oncoprotein functionally interacts with the S4 subunit of the 26 S proteasome. J Biol Chem 1997; 272: 30135-40.
5. Bhui AJ, Bureau JP, Abbas A, Mondal A, Scherrer K, Kurkure A, Therwath A. Novel cellular markers in breast cancer: differential presence of p23K and p30.33K prosomal antigens in tumors of Parsi and non-Parsi women. Int J Oncol 1996; 9: 669-77.
6. Bhui AJ, Bureau JP, Parikh VA, Kukreti R, Scherrer K, Mondal A, Therwath A. Proliferation markers and cell cycle associated expression of prosomes in breast cancers of Parsis and non-Parsis. Int J Oncol 1997; 11: 297-304.
7. Bhui-Kaur AJ, Therwath A, Henry L, Chiesa J, Scherrer K, Kurkure A, Bureau JP. Increased prosomal proteins in breast cancer cells and in neighboring normal cells in Parsi and non-Parsi populations. J Cancer Res Clin Oncol 1998; 124: 117-26.
8. Bies J, Nazarov V, Wolff L. Identification of protein instability determinants in the carboxy-terminal region of c-Myb removed as a result of retroviral integration in murine monocytic leukemias. J Virol 1999; 73: 2038-44.
9. Bureau JP, Henry L, Baz A, Scherrer K, Chateau MT. Prosomes (proteasomes) changes during differentiation are related to the type of inducer. Mol Biol Rep 1997; 24: 57-62.
10. Bureau JP, Olink-Coux M, Brouard N, Bayle-Julien S, Caravano R, Herzberg M, Scherrer K. Prosomes as surface antigens in human lymphocyte subpopulations. Exp Cell Res 1997; 231: 50-60.
11. Chen E, Hrdlickova R, Nehyba J, Longo DL, Bose HR Jr, Li CC. Degradation of proto-oncoprotein c-Rel by the ubiquitin-proteasome pathway. J Biol Chem 1998; 273: 35201-7.
12. Chen F, Chang D, Goh M, Klibanov SA, Ljungman M. Role of p53 in cell cycle regulation and apoptosis following exposure to proteasome inhibitors. Cell Growth Differ 2000; 11: 239-46.
13. Choi YH. Proteasome-mediated degradation of BRCA1 protein in MCF-7 human breast cancer cells. Int J Oncol 2001; 19: 687-93.
14. Ciftci O, Ullrich O, Schmidt CA, Diestel A, Hass R. Regulation of the nuclear proteasome activity in myelomonocytic human leukemia cells after adriamycin treatment. Blood 2001; 97: 2830-8.
15. Clurman BE, Sheaff RJ, Thress K, Groudine M, Roberts JM. Turnover of cyclin E by the ubiquitin-proteasome pathway is regulated by cdk2 binding and cyclin phosphorylation. Genes Dev 1996; 10: 1979-90.
16. Combaret L, Ralliere C, Taillandier D, Tanaka K, Attaix D. Manipulation of the ubiquitin-proteasome pathway in cachexia: pentoxifylline suppresses the activation of 20S and 26S proteasomes in muscles from tumor-bearing rats. Mol Biol Rep 1999; 26: 95-100.
17. Dai Z, Quackenbush RC, Courtney KD, Grove M, Cortez D, Reuther GW, Pendergast AM. Oncogenic Abl and Src tyrosine kinases elicit the ubiquitin-dependent degradation of target proteins through a Ras-independent pathway. Genes Dev 1998; 12: 1415-24.
18. Dietrich C, Bartsch T, Schanz F, Oesch F, Wieser RJ. p53-dependent cell cycle arrest induced by N-acetyl-L-leucinyl-L-leucinyl-L-norleucinal in platelet-derived growth factor-stimulated human fibroblasts. Proc Natl Acad Sci USA 1996; 93: 10815-9.
19. Fanelli M, Minucci S, Gelmetti V, Nervi C, Gambacorti-Passerini C, Pelicci PG. Constitutive degradation of PML/RARalpha through the proteasome pathway mediates retinoic acid resistance. Blood 1999; 93: 1477-81.
20. Freedman DA, Wu L, Levine AJ. Functions of the MDM2 oncoprotein. Cell Mol Life Sci 1999; 55: 96-107.
21. Frisan T, Levitsky V, Masucci MG. Variations in proteasome subunit composition and enzymatic activity in B-lymphoma lines and normal B cells. Int J Cancer 2000; 88: 881-8.
22. Gavioli R, Frisan T, Vertuani S, Bornkamm GW, Masucci MG. c-myc overexpression activates alternative pathways for intracellular proteolysis in lymphoma cells. Nat Cell Biol 2001; 3: 283-8.
23. Glickman MH, Ciechanover A. The ubiquitin-proteasome proteolytic pathway: destruction for the sake of construction. Physiol Rev 2002; 82: 373-428.
24. Golab J, Stoklosa T, Czajka, A, Dabrowska A, Jakobisiak M, Zagozdzon R, Wojcik C, Marczak M, Wilk S. Synergistic antitumor effects of a selective proteasome inhibitor and TNF in mice. Anticancer Res 2000; 20: 1717-21.
25. Goldberg AL, Rock K. Not just research tools - proteasome inhibitors offer therapeutic promise. Nature Med 2002; 8: 338-40.
26. Gregory MA, Hann SR. c-Myc proteolysis by the ubiquitin-proteasome pathway: stabilization of c-Myc in Burkitt's lymphoma cells. Mol Cell Biol 2000; 20: 2423-35.
27. Griscavage JM, Wilk S, Ignarro LJ. Inhibitors of the proteasome pathway interfere with induction of nitric oxide synthase in macrophages by blocking activation of transcription factor NF-kappa B. Proc Natl Acad Sci USA 1996; 93: 3308-12.
28. Hakak Y, Martin GS. Ubiquitin-dependent degradation of active Src. Curr Biol 1999; 9: 1039-42.
29. Hibi K, Westra WH, Borges M, Goodman S, Sidransky D, Jen J. PGP9.5 as a candidate tumor marker for non-small-cell lung cancer. Am J Pathol 1999; 155: 711-5.
30. Higashitsuji H, Itoh K, Nagao T, Dawson S, Nonoguchi K, Kido T, Mayer RJ, Arii S, Fujita J. Reduced stability of retinoblastoma protein by gankyrin, an oncogenic ankyrin-repeat protein overexpressed in hepatomas. Nat Med 2000; 6: 96-9.
31. Hofmann F, Martelli F, Livingston DM, Wang Z. The retinoblastoma gene product protects E2F-1 from degradation by the ubiquitin-proteasome pathway. Genes Dev 1996; 10: 2949-59.
32. Isaacs JS, Saito S, Neckers LM. Requirement for HDM2 activity in the rapid degradation of p53 in neuroblastoma. J Biol Chem 2001; 276: 18497-506.
33. Iwasaka T, Oh-uchida M, Matsuo N, Yokoyama M, Fukuda K, Hara K, Fukuyama K, Hori K, Sugimori H. Correlation between HPV positivity and state of the p53 gene in cervical carcinoma cell lines. Gynecol Oncol 1993; 48: 104-9.
34. Joazeiro CA, Wing SS, Huang H, Leverson JD, Hunter T, Liu YC. The tyrosine-kinase negative regulator c-Cbl a RING type, E2-dependent ubiquitin protein ligase. Science 1999; 286: 309-12.
35. Johnsen AK, France J, Nagy N, Askew D, Abdul-Karim FW, Gerson SL, Sy M-S, Harding CV. Systemic deficits in transporter for antigen presentation (TAP)-1 or proteasome subunit LMP2 have little or no effect on tumor incidence. Int J Cancer 2001; 91: 366-72.
36. Kamura T, Sato S, Iwai K, Czyzyk-Krzeska M, Conaway RC, Conaway JW. Activation of HIF1alpha ubiquitination by a reconstituted von Hippel-Lindau (VHL) tumor suppressor complex. Proc Natl Acad Sci U S A 2000; 97: 10430-5.
37. Kiyomiya K, Matsuo S, Kurebe M. Mechanism of specific nuclear transport of adriamycin: the mode of nuclear translocation of adriamycin-proteasome complex. Cancer Res 2001; 61: 2467-71.
38. Levitskaya J, Sharipo A, Leonchiks A, Ciechanover A, Masucci MG. Inhibition of ubiquitin/proteasome-dependent protein degradation by the Gly-Ala repeat domain of the Epstein-Barr virus nuclear antigen 1. Proc Natl Acad Sci U S A 1997; 94: 12616-21.
39. Lee CW, La Thangue NB. Promoter specificity and stability control of the p53-related protein p73. Oncogene 1999; 18: 4171-81.
40. Liu LF, Desai SD, Li TK, Mao Y, Sun M, Sim SP. Mechanism of action of camptothecin. Ann N Y Acad Sci 2000; 922: 1-10.
41. Lorite MJ, Smith HJ, Arnold JA, Morris A, Thompson MG, Tisdale MJ. Activation of ATP-ubiquitin-dependent proteolysis in skeletal muscle in vivo and murine myoblasts in vitro by a proteolysis-inducing factor (PIF). Br J Cancer 2001; 85: 297-302.
42. McKay BC, Chen F, Clarke ST, Wiggin HE, Harley LM, Ljungman M. UV light-induced degradation of RNA polymerase II is dependent on the Cockayne's syndrome A and B proteins but not p53 or MLH1. Murat Res 2001; 485: 93-105.
43. Mao Y, Desai SD, Ting CY, Hwang J, Liu LF. 26S proteasome-mediated degradation of topoisomerase II cleavable complexes. J Biol Chem 2001; 276: 40652-8.
44. Marshansky V, Wang X, Bertrand R, Luo H, Duguid W, Chinnadurai G, Kanaan N, Vu MD, Wu J. Proteasomes modulate balance among proapoptotic and antiapoptotic Bcl-2 family members and compromise functioning of the electron transport chain in leukemic cells. J Immunol 2001; 166: 3130-42.
45. Mattsson K, Pokrovskaja K, Kiss C, Klein G, Szekely L. Proteins associated with the promyelocytic leukemia gene product (PML)-containing nuclear body move to the nucleolus upon inhibition of proteasome-dependent protein degradation. Proc Natl Acad Sci U S A 2001; 98: 1012-7.
46. Miller JR, Moon RT. Signal transduction through beta-catenin and specification of cell fate during embryogenesis. Genes Dev 1996; 10: 2527-39.
47. Nag A, Bondar T, Shiv S, Raychaudhuri P. The Xeroderma pigmentosum group E gene product ddb2 is a specific target of cullin 4a in mammalian cells. Mol Cell Biol 2001; 21: 6738-47.
48. Nakanishi Y, Pei XH, Takayama K, Bai F, Izumi M, Kimotsuki K, Inoue K, Minami T, Wataya H, Hara N. Polycyclic aromatic hydrocarbon carcinogens increase ubiquitination of p21 protein after the stabilization of p53 and the expression of p21. Am J Respir Cell Mol Biol 2000; 22: 747-54.
49. Naujokat C, Hoffman S. Role and function of the 26S proteasome in proliferation and apoptosis. Laboratory Investigation 2002; 82: 965-80.
50. Ogiso Y, Tomida A, Kim HD, Tsuruo T. Glucose starvation and hypoxia induce nuclear accumulation of proteasome in cancer cells. Biochem Biophys Res Commun 1999; 258: 448-52.
51. Pajonk F, McBride WH. Ionizing radiation affects 26S proteasome function and associated molecular responses, even at low doses. Radiother Oncol 2001; 59: 203-12.
52. Papa FR, Hochstrasser M. The yeast DOA4 gene encodes a deubiquitination enzyme related to a product of the human tre-2 oncogene. Nature 1993; 366: 313-9.
53. Piccinini M, Tazartes O, Mezzatesta C, Ricotti E, Bedino S, Grosso F, Dianzani U, Tovo PA, Mostert M, Musso A, Rinaudo MT. Proteasomes are a target of the antitumour drug vinblastine. Biochem J 2001; 356: 835-41.
54. Pioli PA, Rigby WF. The von Hippel-Lindau protein interacts with heteronuclear ribonucleoprotein a2 and regulates its expression. J Biol Chem 2001; 276: 40346-52.
55. Polakis P. Wnt signalling and cancer. Genes Dev; 2000; 14: 1837-51.
56. Qiao D, Gaitonde SV, Qi W, Martinez JD. Deoxycholic acid suppresses p53 by stimulating proteasome-mediated p53 protein degradation. Carcinogenesis 2001; 22: 957-64.
57. Rubinfeld B, Albert I, Porfiri E, Mukemitsu S, Polakis P. Loss of beta-catenin regulation by the APC tumor suppressor protein correlates with loss of structure due to common somatic mutations of the gene. Cancer Research 1997; 57: 4624-30.
58. Russo SM, Tepper JE, Baldwin AS Jr, Liu R, Adams J, Elliott P, Cusack JC Jr. Enhancement of radiosensitivity by proteasome inhibition: implications for a role of NF-kappaB. Int J Radiat Oncol Biol Phys 2001; 50: 183-93.
59. Saha D, Datta PK, Beauchamp RD. Oncogenic ras represses transforming growth factor-beta /Smad signaling by degrading tumor suppressor Smad4. J Biol Chem 2001; 276: 29531-7.
60. Schoenfeld AR, Parris T, Eisenberger A, Davidowitz EJ, De Leon M, Talasazan F, Devarajan P, Burk RD. The von Hippel-Lindau tumor suppressor gene protects cells from UV-mediated apoptosis. Oncogene 2000; 19: 5851-7.
61. Seliger B, Boch M, Ritz V, Huber C. High frequency of a non-functional TAP1/LMP2 promoter polymorphism in human tumors. Int J Oncol 2002; 20: 349-59.
62. Sharipo A, Imreh M, Leonchiks A, Branden C, Masucci MG. cis-Inhibition of proteasomal degradation by viral repeats: impact of length and amino acid composition. FEBS Lett 2001; 499: 137-42.
63. Sjakste T, Lauberte L, Collan Y, Savontaus M-L, Bajare A, Scherrer K, Sjakste N. Identification of an intronic TG repeat polymorphism in the human proteasome core particle PROS-27 gene. DNA Seq 2002; 13: 139-43.
64. Tanaka T, Rodriguez de la Concepcion ML, De Luca LM. Involvement of all-trans-retinoic acid in the breakdown of retinoic acid receptors alpha and gamma through proteasomes in MCF-7 human breast cancer cells. Biochem Pharmacol 2001; 61: 1347-55.
65. Trapasso F, Iuliano R, Boccia A, Stella A, Visconti R, Bruni P, Baldassarre G, Santoro M, Viglietto G, Fusco A. Rat protein tyrosine phosphatase eta suppresses the neoplastic phenotype of retrovirally transformed thyroid cells through the stabilization of p27(Kipl). Mol Cell Biol 2000; 20: 9236-46.
66. Treier M, Straszewski LM, Bohman D. Ubiquitin-dependent c-jun degradation in vivo is mediated by the delta domain. Cell 1994; 78: 787-90.
67. Tsihlias J, Kapusta L, Slingerland J. The prognostic significance of altered cyclin-dependent kinase inhibitors in human cancer. Ann Rev Med 1999; 50: 401-23.
68. Wada M, Kosaka M, Saito S, Sano T, Tanaka K, Ichihara A. Serum concentration and localization in tumor cells of proteasomes in patients with hematological malignancy and their pathophysiologic significance. J Lab Clin Med 1993; 121: 215-23.
69. Wang J, Sampath A, Raychaudhuri P, Bagchi S. Both Rb and E7 are regulated by the ubiquitin proteasome pathway in HPV-containing cervical tumor cells. Oncogene 2001; 20: 4740-9.
70. Zaika A, Marchenko N, Moll UM. Cytoplasmically "sequestered" wild type p53 protein is resistant to Mdm2-mediated degradation. J Biol Chem 1999; 274: 27474-80.